Highlights from the day 1 of the touchNEUROLOGY expert interviews filmed at AAN 2019 in Philadelphia from May 4-10, 2019.
Share this Video
Related Videos In Multiple Sclerosis
Jiwon Oh, AAN 2022: Tolebrutinib as a potential treatment in relapsing multiple sclerosis – Long-term extension study, phase 2b, 18-month results
Tolebrutinib is an oral, CNS-penetrant Bruton’s tyrosine kinase inhibitor with dual mechanism of action: peripheral B cell modulation and re-establishment of CNS microglial homeostasis. Dr Jiwon Oh (St. Michael’s Hospital, University of Toronto, Canada) joins us to discuss the phase 2b trial (NCT03889639), investigating safety and efficacy of tolebrutinib in patients with relapsing multiple sclerosis. […]
Bruce Cree, AAN 2022: Bruton tyrosine kinase inhibitors in multiple sclerosis – Key clinical highlights
Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the potential use of bruton tyrosine kinase inhibitors (BTKis) in the treatment of multiple sclerosis. Prof. Cree discusses BTKis novel mechanism of action and the rationale behind the investigation of this new class of drugs. Question: What are the key clinical highlights in […]
Bruce Cree, AAN 2022: Disability improvements with ublituximab in relapsing multiple sclerosis – Phase 3 ULTIMATE I and II trials
Ublituximab is a novel glycoengineered monoclonal antibody treatment under investigation for relapsing remitting multiple sclerosis. Prof Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the phase 3 ULTIMATE I and II studies, and the positive results from the tertiary analysis of the data that investigated disability improvements in patients with relapsing multiple […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!